PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsLumacaftor
Orkambi(lumacaftor)
Orkambi (lumacaftor) is a small molecule pharmaceutical. Lumacaftor was first approved as Orkambi on 2015-07-02. It is used to treat cystic fibrosis in the USA. It has been approved in Europe to treat cystic fibrosis. It is known to target cystic fibrosis transmembrane conductance regulator.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
digestive system diseasesD004066
respiratory tract diseasesD012140
hereditary congenital and neonatal diseases and abnormalitiesD009358
Trade Name
FDA
EMA
Combinations
Orkambi
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ivacaftor
+
Lumacaftor
Tradename
Company
Number
Date
Products
ORKAMBIVertex PharmaceuticalsN-206038 RX2015-07-02
2 products, RLD, RS
ORKAMBIVertex PharmaceuticalsN-211358 RX2018-08-07
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
orkambiNew Drug Application2025-07-22
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
cystic fibrosisEFO_0000390D003550E84
Agency Specific
FDA
EMA
Expiration
Code
IVACAFTOR / LUMACAFTOR, ORKAMBI, VERTEX PHARMS INC
2029-09-02ODE-408
2025-09-02NPP, NS
2025-08-07ODE-195
Patent Expiration
Patent
Expires
Flag
FDA Information
Ivacaftor / Lumacaftor, Orkambi, Vertex Pharms Inc
89936002030-12-11DP
85075342030-09-20DS, DP
87163382030-09-20DPU-1718, U-1910, U-2396, U-3426
91926062029-09-29DPU-1912, U-2397, U-3428
106464812029-08-13DP
115649162029-08-13U-3526, U-3529
88467182029-07-02U-1717, U-1908, U-2375, U-3427
86531032028-12-04DP
91505522028-12-04U-1908, U-2375, U-3427
100765132028-12-04DPU-2411
105973842028-12-04DS, DPU-2777, U-2778, U-3430
110520752028-12-04DPU-3181
83242422027-08-05U-1311, U-1911, U-2374, U-3424
74951032027-05-20DS, DP
84102742026-12-28DP
87542242026-12-28DS, DP
96701632026-12-28DPU-1911, U-2376, U-3429
99313342026-12-28DPU-2276, U-2376, U-3429
79730382026-11-08U-1973, U-2374, U-3424
87419332026-11-08U-1717, U-1909, U-2374, U-3424
92169692026-11-08DP
ATC Codes
R: Respiratory system drugs
— R07: Other respiratory system products in atc
— R07A: Other respiratory system products in atc
— R07AX: Other respiratory system products in atc
— R07AX30: Ivacaftor and lumacaftor
HCPCS
No data
Clinical
Clinical Trials
48 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cystic fibrosisD003550EFO_0000390E8455122226
FibrosisD005355———5121220
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lung diseasesD008171EFO_0003818J98.4——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Disease progressionD018450———1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver diseasesD008107EFO_0001421K70-K771————1
Hepatic insufficiencyD048550——1————1
Healthy volunteers/patients———1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLumacaftor
INNlumacaftor
Description
Lumacaftor is an aromatic amide obtained by formal condensation of the carboxy group of 1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropane-1-carboxylic acid with the aromatic amino group of 3-(6-amino-3-methylpyridin-2-yl)benzoic acid. Used for the treatment of cystic fibrosis. It has a role as a CFTR potentiator and an orphan drug. It is a member of benzoic acids, a member of pyridines, an aromatic amide, a member of cyclopropanes, a member of benzodioxoles and an organofluorine compound.
Classification
Small molecule
Drug classcystic fibrosis transmembrane regulator (CFTR) protein modulators
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cc1ccc(NC(=O)C2(c3ccc4c(c3)OC(F)(F)O4)CC2)nc1-c1cccc(C(=O)O)c1
Identifiers
PDB—
CAS-ID936727-05-8
RxCUI—
ChEMBL IDCHEMBL2103870
ChEBI ID—
PubChem CID16678941
DrugBankDB09280
UNII IDEGP8L81APK (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CFTR
CFTR
Organism
Homo sapiens
Gene name
CFTR
Gene synonyms
ABCC7
NCBI Gene ID
1080
Protein name
cystic fibrosis transmembrane conductance regulator
Protein synonyms
ATP-binding cassette sub-family C member 7, cAMP-dependent chloride channel, Channel conductance-controlling ATPase, cystic fibrosis transmembrane conductance regulating, cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7)
Uniprot ID
Q2I102
Mouse ortholog
Cftr (12638)
cystic fibrosis transmembrane conductance regulator (Q9JKQ6)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Orkambi – Vertex Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,998 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
8,224 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use